Riskpilot← Back to searchSign inGet full accessISCOMED AB
ABActiveOrg 5568484223Economic activity was not specified by tax authority · NACE 0000Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
+53% vs 2023
Equity ratio
99.0%
Financial strength
Net profit 2024
SEK -1,7M
-4997% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | +53% |
| Net profit | SEK -1,7M | -4997% |
| Total assets | SEK 2,7M | -39% |
| Equity | SEK 2,7M | -39% |
| Employees | 0 | — |
Legal name
ISCOMED AB
Org number
5568484223
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
4 april 2011
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget ska bedriva förvaltning av fast och lös egendom, konsultverksamhet inom management, bedriva forsknings-, produktions- och utvecklingsarbete syftande till kommersiell exploatering inom luftrening, cancer, mikrobiologi, farmakologi och immunologi inom vaccinområdet samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −82 | −104 | −42 | −34 | −16 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −82 | −104 | −42 | −34 | −16 |
| Net financials | 866 | — | — | — | −3 434 |
| Profit before tax | 784 | −104 | −42 | −34 | −1 733 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 784 | −104 | −42 | −34 | −1 733 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 656 | 4 551 | 4 510 | 4 466 | 2 731 |
| Equity | 4 617 | 4 512 | 4 470 | 4 436 | 2 703 |
| Long-term debt | 0 | 0 | 0 | 0 | 2 |
| Short-term debt | 39 | 39 | 39 | 30 | 30 |
| Total debt | 39 | 39 | 39 | 30 | 32 |
EBITDA margin
-1600000.0%
This company
15.8%
Market median
-10126682% vs market
20202024
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20202024
Return on equity
-64.1%
This company
18.4%
Market median
-448% vs market
20202024
Net profit margin
-173300000.0%
This company
8.1%
Market median
-2139506273% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ISCOMED AB 
Moreinx ABBoard members of ISCOMED AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Monie | Board of Directors | 0 companies |
| Erik Thomas Zetterberg | Board of Directors | 0 companies |
| Lars Johan Yngve Monie | Chairman | 0 companies |
| Jeremy Clark | Board of Directors | 0 companies |